Composition, traditional Chinese medicine, preparation method of traditional Chinese medicine and application of traditional Chinese medicine in hepatitis
By combining traditional Chinese medicine formulas with Yinchen, rhubarb, gardenia, Bupleurum, Schisandra chinensis, Tulip, Turmeric, Alisma, and Perlin, combined with the Qingyangming damp-heat theory of traditional Chinese medicine and the intestinal liver circulation theory of modern medicine, the role of NASH treatment was solved. The problems of single targets and low safety significantly alleviate steatosis and inflammatory responses in hepatocytes and provide new therapeutic ideas.
Patent Information
- Application Number
- CN202410870140.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-01
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing NASH treatment methods have problems such as single targets of action, unsuitable for long-term medication, and low safety. The pathogenesis of non-alcoholic steatohepatitis has not been fully explained, which has brought huge challenges to the development of new drugs.
Using a composition, including Insectomycephala, Rhubarb, Gardenia, Bupleurum, Schisandra chinensis, Tulip, Turmeric, Alisma, and Perlin, through the theory of Qingyangming damp heat, combined with the theory of intestinal liver circulation and intestinal microecology of modern medicine , developed a traditional Chinese medicine formula for the treatment of non-alcoholic steatohepatitis.
This Chinese medicine formula significantly alleviates pathological symptoms such as steatosis and inflammatory cell infiltration in mice, provides new traditional Chinese medicine treatment ideas, is better than some Western medicines, and has significant safety and multiple targets of action.
Smart Images

Figure BDA0004921377980000082 
Figure BDA0004921377980000084 
Figure BDA0004921377980000092
Abstract
Description
Technical Field
[0001] The invention belongs to the field of Chinese medicine preparations, and specifically relates to a composition, a Chinese medicine, a preparation method thereof and an application thereof in hepatitis. Background Art
[0002] Hepatitis is a general term for all liver inflammations. It is caused by the destruction of liver cells and the impairment of liver function due to certain reasons, which leads to a series of physical discomfort symptoms and abnormal liver function indicators. Among them, non-alcoholic fatty liver disease (NAFLD) is a group of metabolic diseases characterized by liver fat accumulation. It will progress to serious liver diseases such as cirrhosis, liver failure, and liver cancer. It will also increase the incidence of extrahepatic diseases such as myocardial infarction and cerebral infarction. It has become the second largest chronic liver disease threatening the health of Chinese people. According to literature reports, the prevalence of NAFLD in ordinary adults is 20% to 33%, which has become the leading cause of liver disease worldwide, posing a serious threat to people's health and bringing a heavy burden to public health. Among them, about 1 / 4 of patients will develop non-alcoholic steatohepatitis (NASH). NASH is a very harmful stage in the NAFLD disease spectrum and a key link in the progression of the entire NAFLD disease from reversible to irreversible. It can lead to cirrhosis and liver cancer and is one of the main causes of end-stage liver disease and liver transplantation. Non-alcoholic steatohepatitis (NASH) is a severe manifestation of non-alcoholic fatty liver disease (NAFLD), characterized by liver cell damage, necrotic inflammation, and accelerated progression of liver fibrosis, which can further develop into cirrhosis and hepatocellular carcinoma. Epidemiological studies estimate that the global prevalence of NASH is as high as 20-25%, and due to changes in lifestyle, its incidence rate has increased year by year, becoming a huge economic burden and a prominent public health issue. The pathogenesis of NASH has not yet been fully elucidated, and the "multiple-hit theory" believes that NASH is the result of the combined effects of multiple factors such as genetics, obesity, insulin resistance, and inflammatory cascade reactions, which also brings huge challenges to the research and development of new NASH drugs.
[0003] At present, the treatment of NASH is mainly lifestyle intervention, such as dietary calorie restriction and exercise. However, this therapy is difficult to maintain and has poor effects on some patients, so the development of new drugs is urgent. Recently, the first FDA-approved drug for the treatment of metabolic-associated fatty liver disease (MASH), Rezdiffra, was launched. Rezdiffra has a unique lipid-lowering function and excellent safety, suggesting that safe drugs focusing on pathological targets have great therapeutic potential. Commonly used Western medicines have limitations such as a single target, unsuitable for long-term medication, and low safety. Traditional Chinese medicine treatment has obvious effects, few adverse reactions, and multiple targets, and is becoming a hot area for research on new NASH-related drugs.
[0004] NAFLD / NASH does not have a specific disease name in traditional Chinese medicine. According to its onset characteristics and symptoms, it can be classified into the categories of "liver disease", "liver accumulation", "fat gas", "fullness", "side pain", etc. According to traditional Chinese medicine theory, the occurrence and development of fatty liver is a long process, and the etiology and pathogenesis of each stage are different. In the NASH stage, the patient's liver pathological manifestations are mainly concentrated in inflammation, liver cell damage, with or without fibrosis. More and more studies have shown that there is a close correlation between "fat accumulation" in the liver in modern medicine and "dampness syndrome" in traditional Chinese medicine. Li Shimao's "Fire Depression and Release" advocates that "dampness suppression and heat transformation" is a very important form of fire transformation. A large number of studies have shown that the theory of "dampness depression and heat transformation" is basically in line with the disease progression trend from simple lipid accumulation to inflammatory damage.
[0005] Therefore, dampness and heat are the main pathogenic factors in the NASH stage, and dampness and heat mainly originate from the Yangming gastrointestinal tract. Combining the theories of "enterohepatic circulation" and "intestinal microecology" in modern medicine, the inventor treats fatty liver by clearing Yangming dampness and heat. Yinchenhao Decoction is a representative prescription for "clearing Yangming dampness and heat", but Yinchenhao Decoction focuses on the lower jiao, and it is difficult to transform the dampness in the middle and upper jiao. On the other hand, when blood and qi are not harmonious, all kinds of diseases arise from changes, and Yinchenhao Decoction alone lacks the function of harmonizing qi and blood. Professor Wang Qingguo, a master of traditional Chinese medicine, studied and obtained the composition and Chinese medicine according to the present invention based on the physiological and pathological characteristics of modern people, and the treatment of NASH by traditional Chinese medicine has significant effects and advantages. Summary of the invention
[0006] The first aspect of the present invention aims to provide a composition.
[0007] The second aspect of the present invention aims to provide a traditional Chinese medicine.
[0008] The purpose of the third aspect of the present invention is to provide a method for preparing the Chinese medicine of the second aspect of the present invention.
[0009] The purpose of the fourth aspect of the present invention is to provide the composition of the first aspect of the present invention and / or the use of the traditional Chinese medicine of the second aspect of the present invention.
[0010] In order to achieve the above-mentioned purpose of the present invention, the technical solution adopted by the present invention is:
[0011] The first aspect of the present invention provides a composition comprising Artemisia capillaris, Rhubarb, Gardenia jasminoides, Bupleurum chinense, Schisandra chinensis, Curcuma aromatica, Curcuma longa, Alisma orientalis, and Cymbidium orientalis.
[0012] Preferably, the composition comprises the following parts by mass: 25-35 parts of Artemisia capillaris, 1-6 parts of Rhubarb, 4-14 parts of Gardenia jasminoides, 4-14 parts of Bupleurum chinense, 4-14 parts of Schisandra chinensis, 5-15 parts of Curcuma aromatica, 5-15 parts of Curcuma longa, 5-15 parts of Alisma orientalis, and 5-15 parts of Cymbidium orientalis.
[0013] Preferably, the composition comprises the following parts by mass: 30-35 parts of Artemisia capillaris, 3-6 parts of Rhubarb, 5-10 parts of Gardenia jasminoides, 5-10 parts of Bupleurum chinense, 5-10 parts of Schisandra chinensis, 10-15 parts of Curcuma aromatica, 10-15 parts of Curcuma longa, 10-15 parts of Alisma orientalis, and 10-15 parts of Cymbidium orientalis.
[0014] Preferably, the composition consists of Artemisia capillaris, Rhubarb, Gardenia jasminoides, Bupleurum chinense, Schisandra chinensis, Curcuma aromatica, Curcuma longa, Alisma orientalis, and Cymbidium orientalis.
[0015] Preferably, the composition consists of 25-35 parts of Artemisia capillaris, 1-6 parts of Rhubarb, 4-14 parts of Gardenia jasminoides, 4-14 parts of Bupleurum chinense, 4-14 parts of Schisandra chinensis, 5-15 parts of Curcuma aromatica, 5-15 parts of Curcuma longa, 5-15 parts of Alisma orientalis, and 5-15 parts of Cymbidium orientalis.
[0016] Preferably, the composition consists of 30-35 parts of Artemisia capillaris, 3-6 parts of Rhubarb, 5-10 parts of Gardenia jasminoides, 5-10 parts of Bupleurum chinense, 5-10 parts of Schisandra chinensis, 10-15 parts of Curcuma aromatica, 10-15 parts of Curcuma longa, 10-15 parts of Alisma orientalis, and 10-15 parts of Cymbidium orientalis.
[0017] Preferably, the rhubarb comprises wine rhubarb.
[0018] The sources and effects of these herbs are:
[0019] Artemisia capillaris: bitter, pungent, slightly cold. Enters the spleen, stomach, liver, and gallbladder meridians. Clears away dampness and heat, promotes bile secretion and relieves jaundice. It is the dried aerial part of Artemisia scoparza Waldst.et Kit. or Artemisia capillaris Thunb. of the Asteraceae family.
[0020] Gardenia: bitter, cold. Entries to the heart, lung, and triple burner meridians. It can relieve heat and relieve restlessness, clear away heat and dampness, cool blood and detoxify; externally used to reduce swelling and relieve pain. It is the dried mature fruit of Gardenia jasminoides Ellis., a plant of the Rubiaceae family.
[0021] Rhubarb: bitter, cold. Enters the spleen, stomach, large intestine, liver, and pericardium meridians. It has the functions of purging and removing stagnation, clearing away heat and purging fire, cooling blood and detoxifying, stopping bleeding, removing blood stasis and promoting menstruation, and removing dampness and jaundice. It is the dried root and rhizome of Rheum palmatum L., Rheumtanguticum Maxim.ex Balf., or Rheum officinale Baill., plants of the Polygonaceae family.
[0022] Bupleurum: bitter, pungent, slightly cold. Enters the liver and gallbladder meridians. Relieves exterior symptoms and fever, soothes the liver and relieves depression, and raises Yang Qi. It is the dried root of Bupleurum chinensie DC. or Bupleurum scoronerifolium Willd. of the Umbelliferae family.
[0023] Schisandra chinensis: sour, sweet, warm. Enters the lung, heart, and kidney meridians. Astringent, invigorating qi and promoting body fluid, nourishing the kidney and calming the mind. It is the dried mature fruit of Schisandra chinensis (Turcz.) Baill. or Schisandra sphenanthera Rehd. et Wils. of the Magnoliaceae family.
[0024] Turmeric: pungent, bitter, warm. It enters the liver and spleen meridians, promotes blood circulation and qi, relieves menstruation and pain. It is the dried rhizome of the ginger plant Curcuma longa.L.
[0025] Curcuma: pungent, bitter, cold; enters the liver, gallbladder, heart, and lung meridians. It can promote blood circulation and relieve pain, promote qi and relieve depression, clear the heart and cool the blood, promote gallbladder and relieve jaundice. It is the dried root of Curcuma rcenyujin Y, H.Chenet C.Ling, Curcuma longaL., Curcuma wangsiensis SGLee et CFLiang or Curcuma phaeocaulis Val. of the ginger family.
[0026] Alisma orientale: sweet, light, cold. Enters the kidney and bladder meridians. It has the functions of promoting diuresis and dispelling dampness, relieving heat, clearing turbidity and lowering lipids. It is the dried tuber of Alisma orientale (Sam.) Juzep. of the family Alismataceae.
[0027] Perilla: pungent, neutral. Enters the spleen, stomach, and lung meridians. Aromatic and dehumidifying, invigorating the spleen and appetite, relieving summer heat. It is the dried aerial part of the plant Perilla fortunei Turcz. of the Asteraceae family.
[0028] Ze Lan: bitter, pungent, slightly warm. Enter the liver and spleen meridians. Promote blood circulation and regulate menstruation, remove blood stasis and eliminate carbuncle, promote diuresis and reduce swelling. It is the dried aerial part of Lycopus lucidus Turcz.vat.hirtus Regel., a plant of the Labiatae family.
[0029] Preferably, the wine rhubarb is: rhubarb processed with rice wine, and the processing method is: take rhubarb slices or pieces, spray with rice wine and mix evenly, the ratio of rhubarb to rice wine is about 10:1, slightly steam, after the rice wine is absorbed, put it in a frying container, fry it dry with low heat until the color deepens, take it out to cool, and sieve out the debris.
[0030] In one embodiment of the present invention, the composition consists of 30 parts of Artemisia capillaris, 3 parts of Rhubarb, 9 parts of Gardenia jasminoides, 9 parts of Bupleurum chinense, 9 parts of Schisandra chinensis, 10 parts of Curcuma aromatica, 10 parts of Curcuma longa, 10 parts of Alisma orientalis, and 10 parts of Cymbopogon citratus.
[0031] The second aspect of the present invention provides a traditional Chinese medicine, characterized in that it comprises the composition of the first aspect of the present invention.
[0032] Preferably, the dosage form of the traditional Chinese medicine includes at least one of granules, tablets, liquids, pills, pastes, and capsules.
[0033] Preferably, the traditional Chinese medicine further comprises other pharmaceutically acceptable excipients.
[0034] Preferably, the pharmaceutically acceptable excipients include at least one of a thickener, a desiccant, a flavoring agent, a colorant, a stabilizer, a binder, a filler, and a lubricant.
[0035] The third aspect of the present invention provides a method for preparing the Chinese medicine of the second aspect of the present invention, characterized in that it comprises the following steps:
[0036] 1) mixing the composition according to claim 1;
[0037] 2) soaking, decocting, centrifuging and filtering to obtain a decoction;
[0038] 3) processing the decoction into dosage forms to obtain.
[0039] Preferably, step 2) comprises: mixing the composition with water in a mass ratio of 1:(1-40), and soaking for 0.5-4 hours;
[0040] Preferably, the decoction comprises: heating to boil, decocting for 0.5 to 4 hours to obtain a decoction.
[0041] Preferably, the decoction can be repeated 1 to 4 times, and the decoctions are combined.
[0042] Preferably, the composition is mixed with water in a mass ratio of 1:(5-20).
[0043] Preferably, the composition is mixed with water in a mass ratio of 1:(8-12).
[0044] Preferably, the dosage form includes at least one of granules, tablets, liquids, pastes, and capsules.
[0045] Preferably, the dosage form is processed according to conventional techniques and conventional excipients are added to form clinically acceptable tablets, granules, capsules, pills, liquids or pastes.
[0046] Preferably, when the dosage form is a liquid, the decoction is obtained by sterilization.
[0047] Preferably, when the dosage form is an ointment, the decoction is concentrated to obtain an extract.
[0048] Preferably, when the dosage form is tablets, the decoction is concentrated and dried to obtain a decoction powder, which is mixed with auxiliary materials and pressed into tablets.
[0049] Preferably, when the dosage form is a granule, the decoction dry powder is taken, mixed with auxiliary materials, and granulated to obtain the granule.
[0050] Preferably, when the dosage form is a capsule, the decoction dry powder or the granules are taken and filled into a capsule to obtain.
[0051] The fourth aspect of the present invention provides use of the composition of the first aspect of the present invention and / or the traditional Chinese medicine of the second aspect of the present invention in the preparation of a treatment for liver disease.
[0052] Preferably, the liver disease comprises hepatitis.
[0053] Preferably, the hepatitis comprises steatohepatitis.
[0054] Preferably, the steatohepatitis comprises non-alcoholic steatohepatitis.
[0055] Preferably, the liver disease is mainly manifested as at least one of "liver disorder", "liver accumulation", "fatness and gas", "fullness", "flank pain", "dampness syndrome", "Yangming disease" and "jaundice".
[0056] In one embodiment of the present invention, provided is the use of the composition of the first aspect of the present invention and / or the traditional Chinese medicine of the second aspect of the present invention in the preparation of a drug for treating non-alcoholic fatty liver disease in mice.
[0057] Preferably, the dosage of the traditional Chinese medicine for treating non-alcoholic fatty liver disease in mice is 13.75 g / (kg·d) to 27.56 g / (kg·d).
[0058] Preferably, the treatment cycle of the traditional Chinese medicine is 4 weeks.
[0059] The beneficial effects of the present invention are:
[0060] The invention combines the modern medical knowledge and characteristics of the disease, and uses Artemisia capillaris, Bupleurum, Schisandra chinensis, Curcuma aromatica, Curcuma longa, Rhizoma Alismatis, Herba Lysimachiae, Fructus Gardeniae, Rhei Radix et Rhizoma Rhei, and Perilla frutescens as the drug composition, which can clear Yangming damp-heat, benefit the dampness of the triple energizer, and regulate qi and blood. The efficacy is verified by clinical and animal experiments, and it is found that the Chinese medicine formula obtained by the invention can significantly reduce the pathological symptoms such as fatty degeneration of mouse liver cells and inflammatory reaction cell infiltration, bringing new ideas to the treatment of non-alcoholic fatty liver disease with traditional Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 To study the effect of liver-clearing and lipid-lowering Chinese medicine on the changes in serum ALT and AST levels in mice with non-alcoholic fatty liver disease.
[0062] Figure 2 To investigate the effects of liver-clearing and lipid-lowering Chinese medicine on the changes in serum IL-1β, IL-10, and TNF-α levels in mice with non-alcoholic fatty hepatitis.
[0063] Figure 3 To study the effects of liver-clearing and lipid-lowering Chinese medicine on the changes in TC, TG, and FFA levels in liver tissue of mice with non-alcoholic fatty hepatitis.
[0064] Figure 4 To study the effects of liver-clearing and lipid-lowering Chinese medicine on the morphological and pathological changes of liver tissue in mice with non-alcoholic fatty liver disease. DETAILED DESCRIPTION
[0065] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0066] For a long time, various schools have held different views on the etiology and pathogenesis of non-alcoholic fatty liver disease. At present, the mainstream concept of traditional Chinese medicine believes that the pathogenesis and manifestations of this disease are different at each stage of progression. In the early stage, patients with simple non-alcoholic fatty liver disease have spleen deficiency and phlegm obstruction as the pathogenesis; in the middle stage, patients with NASH have damp-heat accumulation as the pathogenesis; in the late stage, patients with fatty liver-related cirrhosis have blood stasis as the pathogenesis. The inventor has been engaged in the research and clinical work of related diseases for a long time, and found that the symptoms of patients with non-alcoholic fatty liver disease are mostly damp-heat intertwined, and often accompanied by qi stagnation and blood stasis, rather than simple phlegm and dampness. Traditional Chinese medicine believes that dampness and heat are wrapped, like oil in noodles, which are difficult to separate. Heat is attached to dampness, and if dampness is not removed, heat will not be clear, and if dampness is removed, heat cannot exist alone. Dampness is sticky and easily blocks the circulation of qi and blood, which can cause qi and blood stasis over time. Therefore, the inventor advocates that its pathogenesis focuses on damp-heat accumulation, and the treatment advocates clearing Yangming dampness and heat as the main treatment, supplemented by promoting qi and blood circulation.
[0067] In the present invention, Yinchenhao decoction is the base prescription, in which Yinchen is the main ingredient, bitter, pungent and slightly cold, clearing away heat, promoting dampness and relieving jaundice; Gardenia is the minister, clearing away dampness and heat, so that dampness and heat are removed from the urine; Rhubarb is the adjuvant, relieving heat and clearing the bowels, clearing away heat and removing blood stasis, so that blood stasis and heat are removed from the stool, and the three flavors play the role of clearing Yangming dampness and heat. The triple energizer is the official who decides the drainage, and the waterway comes out of it. This prescription also starts with the triple energizer to remove dampness. Alisma orientalis is sweet and cold, penetrating and clearing, and Ze Lan is bitter and pungent, promoting water and penetrating dampness, and the two expel the water and dampness of the lower energizer. Perilla frutescens is aromatic and pungent, and can eliminate the turbidity, dampness and rot in the middle and upper energizers. Treating the triple energizer together, opening the upper part, unblocking the middle part, and penetrating the lower part, then the dampness and heat will disappear. When blood and qi are not in harmony, all kinds of diseases will arise. Bupleurum is used to soothe the liver and regulate qi, which helps the liver to function normally. Curcuma and turmeric can promote blood circulation and relieve pain, promote qi and relieve depression, and can also promote bile and reduce jaundice. Wuwei nourishes qi and produces body fluid, and neutralizes the medicinal properties. The four together can harmonize qi and blood. The key of all the medicines is to "clear Yangming dampness and heat", and they have the functions of clearing the three burners and harmonizing qi and blood.
[0068] The present invention is further described below in conjunction with examples, in which the liver-clearing and lipid-reducing Chinese medicine is used to represent the Chinese medicine composition prepared by the present invention.
[0069] Example 1
[0070] 1) Take 9g of Bupleurum, 30g of Artemisia capillaris, 9g of Schisandra chinensis, 10g of Curcuma aromatica, 10g of Curcuma longa, 10g of Alisma orientalis, 6g of Zedoariae rhizome, 9g of Gardenia jasminoides, 3g of Rhubarb with wine, and 10g of Cyperus rotundus, chop and mix;
[0071] 2) Place the medicinal materials in a suitable decoction container, add ten times the weight of the medicine to submerge it, and soak it for 1 hour; heat to boiling, simmer on low heat for 45 minutes, separate the decoction, simmer the residue once more according to the method, collect the decoction, and combine the decoctions;
[0072] 3) The decoction is centrifuged and concentrated at high temperature to 27.56 g / mL (i.e., the weight of the crude drug contained in each mL of the decoction).
[0073] Example 2
[0074] 1) Take 9g of Bupleurum, 30g of Artemisia capillaris, 9g of Schisandra chinensis, 10g of Curcuma aromatica, 10g of Curcuma longa, 10g of Alisma orientalis, 6g of Zedoariae rhizome, 9g of Gardenia jasminoides, 3g of Rhubarb with wine, and 10g of Cyperus rotundus, chop and mix;
[0075] 2) Place the medicinal materials in a suitable decoction container, add ten times the weight of the medicine to submerge it, and soak it for 1 hour; heat to boiling, simmer on low heat for 45 minutes, separate the decoction, simmer the residue once more according to the method, collect the decoction, and combine the decoctions;
[0076] 3) Using the vacuum concentration technology, the extract is concentrated and dried to make an extract with an extraction rate of 20%-30%;
[0077] 4) The extract and auxiliary materials (maltose: dextrin: soluble starch = 2:1:1) are mixed in a total ratio of 1:9, granulated, and dried to form granules.
[0078] Example 3
[0079] 1) Take 9g of Bupleurum, 30g of Artemisia capillaris, 9g of Schisandra chinensis, 10g of Curcuma aromatica, 10g of Curcuma longa, 10g of Alisma orientalis, 6g of Zedoariae rhizome, 9g of Gardenia jasminoides, 3g of Rhubarb with wine, and 10g of Cyperus rotundus, chop and mix;
[0080] 2) Place the medicinal materials in a suitable decoction container, add ten times the weight of the medicine to submerge it, and soak it for 1 hour; heat to boiling, simmer on low heat for 45 minutes, separate the decoction, simmer the residue once more according to the method, collect the decoction, and combine the decoctions;
[0081] 3) Using the vacuum concentration technology, the extract is concentrated and dried to make an extract with an extraction rate of 20%-30%;
[0082] 4) Mix the extract with auxiliary materials (dextrin: starch: powdered sugar = 2:2:1) in a ratio of 3:2, granulate and tablet.
[0083] Effect Example: Therapeutic effect of liver-clearing and lipid-lowering Chinese medicine on mice with non-alcoholic fatty liver disease
[0084] 1. Animal Model and Treatment Methods
[0085] 1) Animal model construction
[0086] Fifty 8-week-old male C57BL / 6J mice (22±2g) were adaptively fed for one week and then randomly divided into 5 groups, 10 mice in each group, including: blank group (Chow), methionine-choline deficient diet group (MCD group), liver-clearing and lipid-lowering low-dose treatment group (abbreviated as QGJZL group, i.e. QGJZ-Low dose), liver-clearing and lipid-lowering high-dose treatment group (abbreviated as QGJZH group, i.e. QGJZ-Highdose), and silybin group (Silybin). Silybin was purchased from Tianjin Tasly, catalog number H20040299.
[0087] Blank group: mice were given methionine choline sufficient (MCS) feed (SYSE-Bio, A2003B) and free access to water for 2 weeks.
[0088] Model group: mice were given methionine choline deficient (MCD) feed (SYSE-Bio, A2002B, the same below) and free access to water for 2 weeks.
[0089] The liver-clearing and lipid-lowering low-dose treatment group was given a methionine choline-deficient (MCD) feed with free access to water for 2 weeks.
[0090] The high-dose liver-clearing and lipid-lowering treatment group was given a methionine choline-deficient (MCD) feed with free access to water for 2 weeks.
[0091] Silybin treatment group: The mice were given methionine choline deficient (MCD) diet with free access to water for 2 weeks.
[0092] The experiment was started two weeks after the mice were induced, and oral administration treatment was started from the third week for 4 weeks (7 weeks in total). Among them, the QGJZL group was given 13.75g / (kg·d) of Chinese medicine decoction (prepared in Example 1) by oral administration, and the QGJZH group was given 27.56g / (kg·d) of Chinese medicine decoction (prepared in Example 1) by oral administration. The silybin group was given an equal volume of 55mg / (kg·d). The blank group and the model group were gavaged with an equal volume of sterile saline every day.
[0093] Detection indicators
[0094] After the 7th week, the mice were sampled to collect mouse serum and mouse liver tissue.
[0095] The mouse liver tissue was stained with HE and Oil Red O, and pathological sections were made, and the total triglyceride (TG), total cholesterol (TC), and free fatty acid (FFA) content of the liver tissue were detected. The liver tissue was fixed in paraformaldehyde for 3 days, and then paraffin sections were prepared and stained with hematoxylin-eosin (H&E0 and Oil Red O. The sections were then observed under an optical microscope and photographed. About 100 mg of liver tissue was weighed, homogenized, and centrifuged in turn. The total cholesterol (TC), total triglyceride (TG), and free fatty acid (FFA) of the liver were detected according to the production instructions of Nanjing Jiancheng Bioengineering Research Institute.
[0096] The serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were detected using an automatic biochemical analyzer (model: Beckman Coulter, AU480).
[0097] The ELISA method was used to detect the serum IL-1β, IL-10, and TNF-α levels using interleukin-1β (IL-1β) test kit, interleukin-10 (IL-10) test kit, and tumor necrosis factor-α (TNF-α) test kit (RayBiotech, USA) in strict accordance with the operating procedures.
[0098] 2) Experimental results
[0099] 1. Biochemical effects of liver-clearing and lipid-lowering Chinese medicine on mouse serum
[0100] The serum AST and ALT levels of mice in each group are shown in Table 1. Figure 1 shown.
[0101] Table 1 Changes of AST and ALT in each group of mice (n=10, )
[0102]
[0103] The results showed that the serum AST and ALT levels of mice in the MCD group were significantly increased compared with those in the blank group (P<0.01), and the serum AST and ALT levels of mice in each treatment group were significantly reduced compared with those in the MCD group (P<0.01). All groups of the Qingganjiangzhi prescription were superior to the positive drug silybin group, and the effect of the high-dose group was better than that of the low-dose group, indicating that its therapeutic effect of reducing AST and ALT was dose-dependent.
[0104] The changes in the levels of inflammatory factors in the serum of mice in each group are shown in Table 2. Figure 2 shown.
[0105] Table 2 Levels of serum inflammation-related factors in mice in each group (n=10, )
[0106]
[0107] The results showed that compared with the blank group, the MCD group had significantly increased serum IL-1β and TNF-α levels (P<0.01), and significantly decreased IL-10 levels. After treatment with the Qingganjiangzhi prescription, the IL-1β and TNF-α levels were significantly decreased (P<0.01), and the IL-10 level was significantly increased. The effect of the high-dose group was better than that of the low-dose group, showing a dose-related effect.
[0108] 2. Effects of liver-clearing and lipid-lowering Chinese medicine on lipid accumulation in mouse liver
[0109] The changes of TG, TC and FFA contents in liver tissues of mice in each group are shown in Table 3. Figure 3 shown.
[0110] Table 3 Contents of TG, TC and FFA in liver tissues of mice in each group (n=10, )
[0111]
[0112] Compared with the blank group, the contents of TG, TC, and FFA in liver tissue of the MCD group were significantly increased (P<0.01), and the contents of TG, TC, and FFA in liver tissue of each treatment group were significantly decreased (P<0.01).
[0113] The liver morphology, HE staining and Oil Red O staining pathological sections of mice in each group are shown in Figure 4As shown. The lipid accumulation in the liver of mice in the MCD group was significant, and hepatocytes showed vacuolation and inflammatory infiltration, indicating that the model was successful. The comparison of stained pathological sections of the MCD group with those of the QGJZL group and the QGJZH group showed that the liver-clearing and lipid-lowering Chinese medicine of the present invention can significantly alleviate pathological symptoms such as fatty degeneration of hepatocytes and infiltration of inflammatory reaction cells.
[0114] In summary, the liver-clearing and lipid-lowering Chinese medicine prepared by the present invention can significantly reduce the AST and ALT levels of MCD-induced non-alcoholic fatty hepatitis (NASH) mice. At the same time, the Elisa method showed that the liver-clearing and lipid-lowering Chinese medicine can significantly improve inflammation in mice. On the one hand, it reduces the levels of inflammatory factors IL-1β and TNF-α; on the other hand, it increases the level of anti-inflammatory factor IL-10. The detection of liver lipid indicators showed that the liver-clearing and lipid-lowering Chinese medicine can significantly reduce the content of liver TG, TC, and FFA. The results of liver HE and Oil Red O staining showed that the liver-clearing and lipid-lowering Chinese medicine significantly alleviated pathological symptoms such as fatty degeneration of hepatocytes and infiltration of inflammatory reaction cells, and its effect was better than silybin and was dose-dependent.
Claims
1. A composition, Features: Including Artemisia capillaris, Rhubarb, Gardenia, Bupleurum, Schisandra chinensis, Curcuma, Curcuma longa, Alisma orientalis, and Cymbidium orientalis.
2. The composition according to claim 1, Features: The weight proportions of the medicinal materials in the composition are: 25-35 parts of Artemisia capillaris, 1-6 parts of Rhubarb, 4-14 parts of Gardenia jasminoides, 4-14 parts of Bupleurum chinense, 4-14 parts of Schisandra chinensis, 5-15 parts of Curcuma aromatica, 5-15 parts of Curcuma longa, 5-15 parts of Orientalis orientalis, and 5-15 parts of Cymbidium eupatorium; Preferably, the weight parts of the medicinal materials in the composition are: 30-35 parts of Artemisia capillaris, 3-6 parts of Rhubarb, 5-10 parts of Gardenia jasminoides, 5-10 parts of Bupleurum chinense, 5-10 parts of Schisandra chinensis, 10-15 parts of Curcuma aromatica, 10-15 parts of Curcuma longa, 10-15 parts of Alisma orientalis, and 10-15 parts of Cymbidium orientalis.
3. The composition according to claim 1, Features: The rhubarb is wine rhubarb; Preferably, the preparation method of the wine-cooked rhubarb is: spray the rhubarb with rice wine, and after the rice wine is completely absorbed, fry it over a low fire until it is dry, deepen its color, and then take it out.
4. A Chinese medicine, Features: Comprising the composition of claim 1; Wherein, the dosage form of the traditional Chinese medicine is granules, tablets, liquids, pills, pastes or capsules; Preferably, the traditional Chinese medicine further comprises pharmaceutically acceptable excipients; Preferably, the pharmaceutically acceptable excipients include at least one of a thickener, a desiccant, a flavoring agent, a colorant, a stabilizer, a binder, a filler, and a lubricant.
5. The method for preparing the Chinese medicine according to claim 4, It is characterized in that The following steps are involved: 1) mixing the composition according to claim 1; 2) soaking, decocting, centrifuging and filtering to obtain a decoction; 3) Processing the decoction into dosage form to obtain the product.
6. The preparation method according to claim 5, Features: The step 2) comprises: mixing the composition with water in a mass ratio of 1: (1-40) and soaking for 0.5-4 hours; And / or, the decocting comprises: heating to boil, decocting for 0.5 to 4 hours; Preferably, the decoction is repeated 1 to 4 times, and the decoctions are combined.
7. The preparation method according to claim 6, Features: The dosage form is processed according to conventional techniques and pharmaceutically acceptable excipients are added to prepare clinically acceptable tablets, granules, capsules, pills, liquids or pastes.
8. Use of the composition according to any one of claims 1 to 3 or the traditional Chinese medicine according to claim 4 in the preparation of a medicament for treating hepatitis.
9. The use according to claim 8, Features: The hepatitis includes steatohepatitis.
10. The use according to claim 9, Features: The steatohepatitis includes non-alcoholic steatohepatitis.
Citation Information
Patent Citations
Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN102233119A
Traditional Chinese medicine composition for treating fatty liver and preparation method thereof
CN116832133A
Medicine composition for treating fatty liver and its preparing method
CN1857686A
Cited By
Traditional Chinese medicine composition for treating insomnia as well as preparation method and application thereof
CN119746005A
Traditional Chinese medicine composition for preventing and treating metabolism-related fatty liver diseases or metabolic syndromes
CN120478557A
